院外心脏骤停中强化药物心肺复苏试验:一项先导性随机对照试验
这项在韩国首尔一家三级大学附属医院急诊科开展的双盲、单中心、随机、安慰剂对照先导试验,纳入148例非创伤性院外心脏骤停成人,入选条件为早期胸外按压期间有创动脉监测初始舒张压<20 mmHg。患者随机接受40 IU血管加压素或安慰剂,与初始肾上腺素同时给药。主要终点持续自主循环恢复率在血管加压素组为36.5%(27例),对照组为32.4%(24例),风险差4.1%,P=0.60;出院存活和出院时神经功能结局两组无差异。血管加压素组复苏期间中位舒张压显著高于对照组(16.0 vs 14.5 mmHg,P<0.01)。
要点
- 入选标准:非创伤性院外心脏骤停成人,早期胸外按压期间有创动脉监测初始舒张压<20 mmHg(难治性血管扩张性休克)。
- 干预:40 IU血管加压素与初始肾上腺素同时给药,对照为安慰剂,双盲设计。
- 主要终点持续自主循环恢复率:血管加压素组36.5%(27例)vs 对照组32.4%(24例),风险差4.1%,P=0.60,未达统计学显著。
- 复苏期间中位舒张压:血管加压素组16.0 mmHg vs 对照组14.5 mmHg,P<0.01。
- 出院存活和出院时良好神经功能结局两组无差异;基线、10分钟和结束时呼气末二氧化碳、酸中毒和乳酸水平无差异。
适用人群与场景
- 非创伤性院外心脏骤停成人,在急诊科接受心肺复苏,早期胸外按压期间有创动脉监测初始舒张压<20 mmHg。
诊断标准与关键阈值
- 入选标准:早期胸外按压期间有创动脉监测初始舒张压<20 mmHg。
处置流程与药物剂量
- 血管加压素40 IU与初始肾上腺素同时给药(给药途径原文未写明)。
- 对照组给予安慰剂与初始肾上腺素同时给药。
研究设计与关键结果
- 研究设计:双盲、单中心、随机、安慰剂对照先导试验,在韩国首尔一家三级大学附属医院急诊科开展;共筛查180例,排除32例,纳入148例成人非创伤性院外心脏骤停患者。
- 主要终点持续自主循环恢复率:血管加压素组36.5%(27例)vs 对照组32.4%(24例),风险差4.1%,P=0.60。
- 复苏期间中位舒张压:血管加压素组16.0 mmHg vs 对照组14.5 mmHg,P<0.01。
- 出院存活和出院时良好神经功能结局两组无差异。
- 基线、10分钟和结束时呼气末二氧化碳、酸中毒和乳酸水平两组无差异。
证据类型、等级与局限
- 证据类型:双盲、单中心、随机、安慰剂对照先导试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于院外心脏骤停中难治性血管扩张性休克患者,与安慰剂相比,给予血管加压素未显著增加自主循环恢复的可能性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Previously conducted physician-centered trials on the usefulness of vasopressin have yielded negative results; thus, patient-oriented trials have been warranted. We hypothesize that Augmented-Medication CardioPulmonary Resuscitation could be helpful for selected patients with out-of-hospital cardiac arrest (OHCA).
METHODS: This is a double-blind, single-center, randomized, placebo-controlled trial conducted in the emergency department in a tertiary, university-affiliated hospital in Seoul, Korea. A total of 148 adults with non-traumatic OHCA who had initial diastolic blood pressure (DBP) < 20 mm Hg via invasive arterial monitoring during the early cardiac compression period were randomly assigned to two groups. Patients received a dose of 40 IU of vasopressin or placebo with initial epinephrine. The primary endpoint was a sustained return of spontaneous circulation. Secondary endpoints were survival discharge, and neurologic outcomes at discharge.
RESULTS: Of the 180 included patients, 32 were excluded, and 148 were enrolled in the trial. A sustained return of spontaneous circulation was achieved by 27 patients (36.5%) in the vasopressin group and 24 patients (32.4%) in the control group (risk difference, 4.1%; P = .60). Survival discharge and good neurologic outcomes did not differ between groups. The trial group had significantly higher median DBPs during resuscitation than the control group (16.0 vs. 14.5 mm Hg, P < 0.01). There was no difference in end-tidal carbon dioxide, acidosis, and lactate levels at baseline, 10 min, and end-time.
CONCLUSION: Among patients with refractory vasodilatory shock in OHCA, administration of vasopressin, compared with placebo, did not significantly increase the likelihood of return of spontaneous circulation.
参考来源
- Kim JS, Ryoo SM, Kim YJ, et al. Augmented-Medication CardioPulmonary Resuscitation Trials in out-of-hospital cardiac arrest: a pilot randomized controlled trial. Crit Care. 2022. PMID: 36476543. doi:10.1186/s13054-022-04248-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。